Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectrophotometric detection

Clinical Chemistry

Volumn 51, Issue 9, 2005, Pages 1718-1721

  Kirschbaum, Katrin M ^a   Müller, Matthias J ^a   Zernig, Gerald ^b   Saria, Alois ^b   Mobascher, Arian ^c   Malevani, Jaroslav ^c   Hiemke, Christoph ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT;

ARTICLE; BLOOD SAMPLING; CALIBRATION; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; QUALITY CONTROL; SCHIZOPHRENIA; SPECTROPHOTOMETRY;

ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; HUMANS; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 24144445638     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.049809     Document Type: Article

References (11)

1. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004;483:45-53.
2. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400-11.
3. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-71.
4. Bristol-Myers Squibb Company and Otsuka America Pharmaceutical Inc. Abilify® (aripiprazole) tablets prescribing information. http://www.abilify. com (accessed July 2005).
5. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004;44:179-87.
6. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004;37:243-65.
7. Perry PJ. Therapeutic drug monitoring of antipsychotics. Psychopharmacol Bull 2001;35:19-29.
8. Härtter S, Weigmann H, Hiemke C. Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultra-violet detection. J Chromatogr B 2000;740:135-40.
9. Zernig G, De Wit H, Telser S, Nienhusmeier M, Wakonigg G, Sturm K, et al. Subjective effects of slow-release bupropion vs. caffeine as determined in a quasi-naturalistic setting. Pharmacology 2004;70:206-15.
10. Clinical and Laboratory Standards Institute (CLSI). Evaluation of precision performance of clinical chemistry devices. NCCLS/CLSI Document EP5-T2. Wayne, PA: CLSI. 1992.
11. 11C]raclopride. Neuropsychopharmacology 2002;27: 248-59.